Kindeva Drug Delivery
This sponsor has funded 1 studies across 23 countries.
| EU PAS ID | Status | Title | Protocol uploaded | Results uploaded |
|---|---|---|---|---|
| 39494 | Finalised | Expert opinion on the impact of inhaler choice on climate change and personalised healthcare | Yes | No |
PAS by Risk Management Plan (RMP) requirement
Kindeva Drug Delivery
The RMP for a medical product outlines strategies to identify, assess, and mitigate risks, including PAS for further evaluation.
Category 1 studies are imposed as condition of marketing authorisation.
Category 2 studies are imposed as specific obligation of marketing authorisation.
Category 3 studies are required under other circumstances.
PAS by study status
Kindeva Drug Delivery
The study status is defined according to the timeline dates specified.
Planned studies have not collected any data yet.
Ongoing studies collect data and should publish protocols as soon as possible.
Finalised studies should publish results in the first two weeks after finalisation.
Countries
Kindeva Drug Delivery
23 Study countries specified are the following:
- Australia
- Austria
- Belgium
- Canada
- Denmark
- Finland
- France
- Germany
- Greece
- Iceland
- Ireland
- Italy
- Japan
- Korea, Republic of
- Netherlands
- Norway
- Portugal
- Singapore
- Spain
- Sweden
- Switzerland
- United Kingdom
- United Kingdom (Northern Ireland)